Japan-based Solasia Pharma K. K (TYO: 4597) has announced a licensing agreement with Changchun GeneScience Pharmaceutical Co., Ltd, granting the Chinese company exclusive commercialization rights to its oncology product episil oral liquid (sodium valproate) in mainland China, Hong Kong, Macau, and Taiwan. The agreement is effective as of the beginning of 2025.
Commercialization Strategy and Capabilities
GeneScience will leverage its extensive sales network and professional marketing capabilities to enhance the promotion of episil in China. This strategic move aims to expand the product’s reach and accessibility to patients in the region. Financial details of the agreement were not disclosed.
Product Background and Technology
Episil oral liquid is a liquid formulation designed for the management of pain from oral mucositis associated with chemotherapy or radiotherapy. It was developed using Sweden-based Camurus AB’s FluidCrystal technology. Solasia initially obtained exclusive agent rights to the drug in China and Japan from Camurus, with the territories expanding to a global scale in 2022. Episil received approval in China in February 2019, marking a significant milestone in its development and commercialization journey.-Fineline Info & Tech
